Selected article for: "virus wide range and wide range"

Author: Chang, Raymond; Ng, Tzi Bun; Sun, Wei-Zen
Title: Lactoferrin as potential preventative and treatment for COVID-19
  • Cord-id: spj7ac4y
  • Document date: 2020_7_30
  • ID: spj7ac4y
    Snippet: The novel coronavirus 2019 (COVID-19) pandemic is rapidly advancing across the globe despite drastic public and personal health measures. Antivirals and nutritional supplements have been proposed as potentially useful against SARS-CoV-2 (virus that causes COVID-19), but few have been clinically established. Lactoferrin (Lf) is a naturally occurring and non-toxic glycoprotein that is orally available as a nutritional supplement and has established in vitro anti-viral efficacy against a wide range
    Document: The novel coronavirus 2019 (COVID-19) pandemic is rapidly advancing across the globe despite drastic public and personal health measures. Antivirals and nutritional supplements have been proposed as potentially useful against SARS-CoV-2 (virus that causes COVID-19), but few have been clinically established. Lactoferrin (Lf) is a naturally occurring and non-toxic glycoprotein that is orally available as a nutritional supplement and has established in vitro anti-viral efficacy against a wide range of virus including SARS-CoV, a closely related corona virus to SARS-CoV-2 (virus that causes COVID-19). Furthermore, Lf possesses unique immunomodulatory and anti-inflammatory effects that may be especially relevant to the pathophysiology of severe COVID-19 cases. We review the underlying biological mechanisms of Lf as an antiviral and immune regulator, and propose its unique potential as a preventative and adjunct treatment for COVID-19. We hope that further research and development of Lf nutritional supplementation would establish its role for COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acute phase and low dose treatment: 1
    • acute phase and lps administration: 1, 2, 3, 4, 5
    • acute phase and lps injection: 1, 2
    • acute phase and lps lipopolysaccharide injection: 1
    • acute respiratory distress and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory distress and adjunct treatment: 1, 2, 3, 4
    • acute respiratory distress and low affinity: 1, 2
    • acute respiratory distress and low dose treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory distress and lps administration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory distress and lps injection: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory distress and lps lipopolysaccharide injection: 1, 2, 3
    • adhesion molecule and lps injection: 1, 2
    • adjunct treatment and low dose treatment: 1
    • low dose treatment and lps administration: 1
    • low dose treatment and lps injection: 1